Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® for the treatment of chronic gout. Savient has exclusive worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University and Mountain View Pharmaceuticals, Inc. Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. For further information, visit the Company’s Web site at www.savient.com.

Noble Financial, a research driven, full-service investment banking boutique, is as discriminating with its invitations to institutional investors as it is with the companies invited to present. Rather than just focusing on crowding the conference floor, Noble Financial carefully invites a smaller audience of investors with a large appetite for the companies presenting; quality always trumps quantity. For more information or to view webcasts of today’s presentations, visit www.noblefcm.com.

Let us hear your thoughts below: